Inverse agonism and its therapeutic significance

Indian Journal of Pharmacology

Volumn 43, Issue 5, 2011, Pages 492-501

  Khilnani, Gurudas ^a   Khilnani, Ajeet Kumar ^b  

^a RNT MEDICAL COLLEGE   (India)

^b J L N MEDICAL COLLEGE   (India)

Author keywords

Constitutive activity; G protein coupled receptors; inverse agonism; inverse agonists

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ALPRAZOLAM; ALPRENOLOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; ANTIHISTAMINIC AGENT; ANTINOCICEPTIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BUCINDOLOL; CANDESARTAN; CARVEDILOL; CLOZAPINE; DICHLORISOPRENALINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; LABETALOL; METOPROLOL; NADOLOL; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PIMAVANSERIN; PINDOLOL; PROPRANOLOL; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; TIMOLOL; UNINDEXED DRUG;

ALLELE; ARTICLE; BINDING ASSAY; CALCIUM MOBILIZATION; CARDIOSELECTIVITY; CONFORMATIONAL TRANSITION; CONGESTIVE HEART FAILURE; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; FORCED EXPIRATORY VOLUME; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROPHILICITY; IN VITRO STUDY; INVERSE AGONISM; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; OPIATE ADDICTION; PARKINSON DISEASE; PROTEIN EXPRESSION; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION;

EID: 80053366914     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.84947     Document Type: Article

References (68)

1. Kenakin TP. Drug efficacy at G Protein-Coupled receptors. Annu Rev Pharmacol Toxicol 2002;42:349-79.
2. Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006;27:92-6.
3. Labarre M, Butterworth J, St-Onge S, Payza K, Schmidhammer H. Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. Eur J Pharmacol 2000;406:R1-3.
4. Kenakin T. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. FASEB J 2001;15:598-611.
5. Braestrup C, Schmiechen R, Neef G, Nielsen RA, Petersen EN. Interaction of convulsive ligands with benzodiazepine receptors. Science 1982;216:1241-3.
6. Spiegel AM, Weinstein LS. Inherited diseases involving G Proteins and G Protein-coupled receptors. Annu Rev Med 2004;55:27-39.
7. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of beta2-adrenergic receptor over expression in mouse hearts: Critical role for expression level. Circulation 2000;101:1707-14.
8. Dupré DJ, Le Gouill C, Gingras D, Rola-Pleszczynski M, Stanková J. Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor. J Pharmacol Exp Ther 2004;309:102-8.
9. Engelhardt S, Grimmer Y, Fan GH, Lohse MJ. Constitutive activity of the human β1-adrenergic receptor in β1-receptor transgenic mice. Mol Pharmacol 2001;60:712-7.
10. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 1994;45:490-9.
11. Baker JG, Hall IP, Hill SJ. Agonist and inverse agonist actions of β-Blockers at the human β2- ARs provide evidence for agonist-directed signaling. Mol Pharmacol 2003;64:1357-69.
12. Gurdal H. Inverse agonism at β-adrenergic receptors: Therapeutic implications. Expert Rev Neurother 2002;2:261-9.
13. 2 double knockout mice. Mol Pharmacol 2000;58:887-94.
14. Nagaraja S, Iyer S, Liu X, Eichberg J, Bond RA. Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic beta2-adrenoceptor activation. Br J Pharmacol 1999;127:1099-104.
15. Keating GM, Jarvis B. Carvedilol, A review of its use in chronic congestive heart failure. Drugs 2003;63:1697-741.
16. Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, Bohm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000;130:1131-9.
17. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
18. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation 2000;102:484-6.
19. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
20. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, et al. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. Circulation 1994;90:I-543.
21. Verniero C, Höcht C, Opezzo JA, Taira C. Changes in the in vitro Pharmacodynamic properties of metoprolol in atrial myocardium isolated from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2007;34:161-5.
22. Liggett SB. ß-Adrenergic receptors in the failing heart: The good, the bad, and the unknown. J Clin Invest 2001;107:947-8
23. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 2000;101:1634-7.
24. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 1996;17 Suppl B:8-16.
25. 2A-adrenergic receptor. Mol Pharmacol 2001;59:532-42.
26. 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. Proc Natl Acad Sci U S A 1992;88:11354-8.
27. Vazquez SM, Mladovan AG, Perez A, Baldi A Luthy IA. Human breast cell lines exhibit functional alpha2-adrenoceptors. Cancer Chemother Pharmacol. 2006;58:50-61
28. Liu JG, Prather PL. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 2001;60:53-62.
29. Gonzalez-Cabrera PJ, Shi T, Yun J, McCune DF, Rorabaugh BR, Perez DM. Differential regulation of the cell cycle by alpha1-adrenergic receptor subtypes. Endocrinology 2004;145:5157-67.
30. Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H, et al. Two G-protein oncogenes in human endocrine tumors. Science 1990;249:655-9.
31. 2-Adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol 2008;155:494-504.
32. Murphy JM, Jackie J, Mellor-Burke J, Lumeng L, Li T. BDZ inverse agonist RO15-4513 exerts prolonged and selective suppression of ethanol intake in alcohol preferring Rats. Psychopharmacology 1994;115:325-31.
33. Sieghart W. Pharmacology of benzodiazepine receptors: An update. J Psychiatry Neurosci 1994;19:24-9.
34. A receptor benzodiazepine site. Neuropharmacology 2007;53:574-82.
35. Pinna G, Galici R, Herbert H, Schneider H, Stephens DN, Turski L. Alprazolam dependence prevented by substituting with the β- carbolineabecarnil. Proc Natl Acad Sci U S A 1997;94:2719-23.
36. Cruz SL, Villarreal JE, Volkow ND. Further evidence that naloxone acts as an inverse opiate agonist: Implications for drug dependence and withdrawal. Life Sci 1996;26:PL381-9.
37. Costa T, Herz A. Antagonists with negative intrinsic activity at d opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A 1989;86:7321-5.
38. Wang Z, Bilsky EJ, Porreca F, Sadee W. Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 1994;54:L339-50.
39. Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98.
40. 1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein. J Biol Chem 2004;279:34431-9.
41. Simons FE. Advances in H1 antihistamines. N Engl J Med 2004;351:2203-17.
42. Leurs R, Church MK, Taglialatela M. Antihistamines: Inverse H1- agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98.
43. 2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. Mol Pharmacol 2003;64:512-20.
44. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000;408:860-4.
45. Netzer P, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999;94:351-7.
46. 3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur J Neurosci 2003;2:307-14.
47. 3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: Role of the histaminergic system and potential pharmacokinetic interactions. Psychopharmacology (Berl) 2009;202:673-87.
48. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000;295:226-32.
49. 1B receptor inverse agonism affect learning consolidation? Neurosci Biobehav Rev 2001;2:193-201.
50. Purohit A, Smith C, Herrick-Davis K, Teitler M. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: Inverse agonist activity of antipsychotic drugs. Psychopharmacology (Berl) 2005;179:461-9.
51. Meltzer HY, Roger-Mills R, Revell S, Williams H, Johnson A, Bahr D. Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. Neuropsychopharmacology 2010;35:881-92.
52. Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, et al. APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia. Sleep 2008;31:1663-71.
53. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 1999;126: 665-72.
54. 1 cannabinoid receptors. Proc Natl Acad Sci U S A 2007;104:20588-93.
55. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS, et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003;14:573-82.
56. Lunn CA, Reich EP, Fine JS, Lavey B, Kozlowski JA, Hipkin RW, et al. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 2008;153:226-39.
57. Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, et al. Multivalent ligand-receptor interactions elicit inverse agonist activity of AT(1) receptor blockers against stretch-induced AT(1) receptor activation. Hypertens Res 2009;32:875-83.
58. Yasuda N, Akazawa H, Qin Y, Zou Y, Komuro I. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol 2008;377:393-9.
59. Chowdhury BA, Pan GD. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71.
60. Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 2004;101:4948-53.
61. Nguyen LP, Omoluabi O, Parra S, Joanna M, Frieske JM, Clement C, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008;38:256-62.
62. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002:CD002992.
63. Bond RA. Is paradoxical pharmacology a strategy worth pursuing? Trends Pharmacol Sci 2001;22:273-6.
64. Penn RB. Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol 2008;378:149-69.
65. Singh BN, Whitlock RM, Comber RH, Williams FH, Harris EA. Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther 1976;19:493-501.
66. Griffon N, Pilon C, Sautel F, Schwartz C, Sokoloff P. Antipsychotics with inverse agonist actions on D3 receptors. J Neural Transm 1996;103:1163-75.
67. 35S] binding. J Pharmacol Exp Ther 1998;285:119-26.
68. 2 dopamine receptors. Br J Pharmacol 2005;145:34-42.